closing off two escape routes simultaneously
At the edge of what medicine can currently offer cancer patients, a Hong Kong biopharmaceutical company arrives in Chicago with more than forty clinical studies and a question encoded in its science: can antibodies engineered to block two pathways at once outperform the single-target drugs that have defined a generation of oncology? Akeso's ivonescimab has earned the rarest of conference honors — a plenary slot at ASCO 2026 — where survival data from a Phase III lung cancer trial will be placed before the global oncology community for judgment. The moment is significant not merely for one drug or one company, but for the broader wager that biological complexity, met with equal therapeutic complexity, might finally bend the survival curves that have resisted so much effort.
- A bispecific antibody designed to block both PD-1 and VEGF simultaneously has outperformed a standard PD-1 inhibitor in a Phase III lung cancer trial — a result consequential enough to earn the most coveted presentation slot in oncology.
- The HARMONi-6 overall survival data lands on May 31st before an audience of oncologists and investors who understand that a plenary selection is a signal, not a guarantee — scrutiny will be intense.
- Akeso is not resting its case on a single drug: ivonescimab appears across lung, colorectal, and head and neck cancers, while cadonilimab spans renal cell carcinoma, melanoma, biliary tract, and gynecologic malignancies.
- A third agent targeting CD47 and an AI-powered discovery platform round out a portfolio designed to project the image of a durable innovation engine, not a single-asset story.
- Regulatory approval and commercial translation remain genuinely uncertain — the company itself names manufacturing risk, competitive pressure, and the stubborn gap between trial success and real-world outcomes.
Akeso, a Hong Kong-listed biopharmaceutical company, will present more than 40 clinical studies at the American Society of Clinical Oncology's annual meeting in Chicago — a showing anchored by one late-breaking abstract selected for the plenary session, the conference's highest distinction. That centerpiece is ivonescimab, a bispecific antibody engineered to block PD-1 and VEGF simultaneously, two pathways cancer cells exploit to survive and spread. The Phase III HARMONi-6 trial tested ivonescimab plus chemotherapy against tislelizumab — a conventional PD-1 inhibitor — plus chemotherapy in advanced squamous non-small cell lung cancer. Professor Shun Lu of Shanghai Chest Hospital will present the overall survival results on May 31st, in a slot reserved for work with genuine practice-changing potential.
The breadth of Akeso's ASCO presence signals a deliberate strategy: ivonescimab appears across small-cell lung cancer, metastatic colorectal cancer, and head and neck cancer, while cadonilimab — targeting PD-1 and CTLA-4 — features in studies spanning renal cell carcinoma, melanoma, biliary tract cancer, and gynecologic malignancies. A third agent, ligufalimab, targeting CD47, rounds out the portfolio. Founded in 2012, Akeso claims more than 50 assets in development, 27 already in human trials, and seven drugs on the market — a volume meant to demonstrate a functioning innovation engine rather than a single fortunate molecule.
Still, the company's own announcement carries the pharmaceutical industry's familiar caveat: no trial result, however prestigious its venue, guarantees regulatory approval or commercial success. What the oncology world will watch for is whether ivonescimab's survival advantage holds under scrutiny, whether it extends meaningfully across tumor types, and whether the path from promising data to approved medicine proves as navigable as Akeso hopes.
Akeso, a Hong Kong-listed biopharmaceutical company, will bring more than 40 clinical studies to the American Society of Clinical Oncology's annual meeting in Chicago next week, staking a significant claim on the future of cancer treatment. The company's showcase includes one late-breaking abstract selected for the plenary session—the highest honor a conference can bestow—along with four oral or rapid oral presentations. For a company built on the premise that antibodies engineered to hit multiple targets simultaneously could outperform single-target drugs, this is validation of a particular scientific bet.
The centerpiece is ivonescimab, a bispecific antibody that simultaneously blocks PD-1 and VEGF, two distinct pathways that cancer cells exploit to survive and spread. The Phase III HARMONi-6 study tested whether ivonescimab combined with chemotherapy could extend survival in patients with advanced squamous non-small cell lung cancer compared to tislelizumab, a conventional PD-1 inhibitor, also paired with chemotherapy. Professor Shun Lu from Shanghai Chest Hospital will present these overall survival results on May 31st during the plenary session—a slot reserved for work that could reshape how doctors treat disease.
The breadth of Akeso's presentation portfolio suggests the company is not betting everything on a single drug or cancer type. Ivonescimab appears across multiple tumor categories: small-cell lung cancer that has progressed after initial chemoimmunotherapy, metastatic colorectal cancer in the first-line setting, and head and neck cancer in a neoadjuvant trial. Cadonilimab, the company's other lead bispecific antibody, which targets PD-1 and CTLA-4, features in studies spanning renal cell carcinoma, melanoma, colorectal cancer, biliary tract cancer, and gynecologic malignancies. A third agent, ligufalimab—a next-generation antibody targeting CD47—rounds out the oncology portfolio on display.
Akeso was founded in 2012 and has constructed what it calls a Tetrabody antibody technology platform, alongside AI-powered drug discovery, dual-shield antibody-drug conjugate technology, and cell therapy capabilities. The company claims more than 50 assets in development across cancer, autoimmune disease, inflammation, and metabolic disease, with 27 candidates already in human trials and seven drugs already on the market. The sheer volume of work being presented at ASCO—more than 40 studies—is meant to signal that this is not a one-hit wonder but a company with a functioning innovation engine.
Yet the announcement carries the standard pharmaceutical caveat: there is no guarantee that any of these candidates will win regulatory approval or achieve commercial success. The company acknowledges risks ranging from manufacturing delays to competitive pressure to the simple fact that drugs that work in trials sometimes fail in the real world. The plenary presentation of HARMONi-6 data will be closely watched by oncologists and investors alike, but a single positive trial, however prestigious its venue, does not determine a drug's ultimate fate. What matters now is whether the survival advantage ivonescimab demonstrated in this lung cancer population holds up under scrutiny, whether it translates to other cancers, and whether the regulatory pathway to approval moves as smoothly as Akeso hopes.
Citas Notables
The maturity and breadth of these datasets underscore the success of Akeso's innovation engine, demonstrating the clinical benefits of the Company's differentiated bispecific antibody platform to the international oncology community.— Akeso, Inc.
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that ivonescimab targets two pathways instead of one?
Cancer cells are adaptive. A PD-1 inhibitor alone can work, but tumors often find ways around it—sometimes by ramping up VEGF signaling, which promotes new blood vessel growth. By hitting both at once, you're closing off two escape routes simultaneously. That's the theory, anyway.
And HARMONi-6 proved that works?
It showed a survival advantage in squamous lung cancer when ivonescimab was paired with chemotherapy versus a single PD-1 inhibitor with chemotherapy. But that's one cancer type, one patient population. The question now is whether that benefit holds across the other cancers Akeso is testing it in.
Why present at ASCO instead of just publishing the data?
ASCO is where oncologists gather to see what's coming. A plenary slot means the conference organizers think this work could change practice. It's visibility, credibility, and a chance to shape the conversation before competitors do.
Is Akeso a household name in oncology?
Not yet. They're a Hong Kong company that's been building quietly for over a decade. This week is partly about introducing themselves to the American and international oncology establishment. Forty studies is a way of saying: we're not a one-drug company, and we're not going away.
What could go wrong from here?
Manufacturing scale-up, regulatory delays, safety signals that don't show up until larger populations are treated, or simply that the survival advantage in lung cancer doesn't translate to other cancers. And there's always competition—other companies are working on similar bispecific approaches.